ID=H0756
URL=http://hiv-web.lanl.gov/content/hiv-db/REVIEWS/articles/Brander96.html
SIZE=45181
DATE=11/07/2002
TIME=17:07:54
DATASET=Biology
HTML=  
<html>
  <head>
    <title></title>
      <style type="text/css">
	<!--
	  span.red {color: red}
	  span.green {color: green}
          span.small {size:"-1"}
	  input.lavender {background: lavender;
			  color: green}
	  ul.tip {list-style-type: none} 
	  .a11 {color: black; 
                font-size: 11pt; 
                font-weight: normal; 
                text-decoration: none; 
                font-family: Arial, Helvetica, sans-serif}
          a:link {color: blue; 
                  text-decoration : none; 
                  font-weight: normal}
	  a:visited {color : blue;
                     text-decoration : none;
                     font-weight : normal}
          a:hover {color: brown; 
                   text-decoration : none; 
                   font-weight: normal}
#pup {position:absolute; visibility:hidden; z-index:200; width:130; }
//-->
      </style>	
  </head>
  <body bgcolor="white">
    <table bgcolor="white" width="100%" border=0 cellspacing=0 cellpadding=3>
      <tr valign="top">
	<td width="10%" bgcolor="#eaeaea">
               <!--
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>

<HEAD>
  <TITLE>
    HIV sequence database navigation frame
  </TITLE>
</HEAD>


<BODY> 
	BACKGROUND="" 
	BGCOLOR="#eaeaea" 
	TEXT="#000000" 
	LINK="#0000ff" 
	VLINK="#800080" 
	ALINK="#ff0000"
-->

<A HREF="/content/hiv-db/mainpage.html">
	
<IMG SRC="/content/hiv-db/IMAGES/VirusTransparent.gif" BORDER=0></A>

<P>
<CENTER>
</CENTER>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerDatabases.gif" BORDER=0></A><BR>

<A HREF="/content/hiv-db/mainpage.html" 
	onMouseOver="document.Sequence.src='/content/hiv-db/NAVIFRAME/YELLOW/_SequenceDB.gif' "
	onMouseOut="document.Sequence.src='/content/hiv-db/NAVIFRAME/YELLOW/SequenceDB.gif' " >
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SequenceDB.gif" BORDER=0 NAME="Sequence"></A><BR>

<A HREF="http://resdb.lanl.gov/Resist_DB/default.htm" 
	onMouseOver="document.Resistance.src='/content/hiv-db/NAVIFRAME/YELLOW/_ResistanceDB.gif' "
	onMouseOut="document.Resistance.src='/content/hiv-db/NAVIFRAME/YELLOW/ResistanceDB.gif'">
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/ResistanceDB.gif" BORDER=0 NAME="Resistance"></A><BR>

<A HREF="/content/immunology/index" 
	onMouseOver="document.Immunology.src='/content/hiv-db/NAVIFRAME/YELLOW/_ImmunologyDB.gif' "
	onMouseOut="document.Immunology.src='/content/hiv-db/NAVIFRAME/YELLOW/ImmunologyDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/ImmunologyDB.gif" BORDER=0 NAME="Immunology"></A><BR>

<A HREF="/content/vaccine/html/index.html" 
	onMouseOver="document.VaccineTrials.src='/content/hiv-db/NAVIFRAME/YELLOW/_VaccinetrialsDB.gif' "
	onMouseOut="document.VaccineTrials.src='/content/hiv-db/NAVIFRAME/YELLOW/VaccinetrialsDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/VaccinetrialsDB.gif" BORDER=0 NAME="VaccineTrials"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<P>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerPublications.gif" BORDER=0></A><BR>

<A HREF="/content/hiv-db/HTML/FAQ.html" 
	onMouseOver="document.Faq.src='/content/hiv-db/NAVIFRAME/YELLOW/_FAQ.gif' "
	onMouseOut="document.Faq.src='/content/hiv-db/NAVIFRAME/YELLOW/FAQ.gif' ">
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/FAQ.gif" BORDER=0 NAME="Faq"></A><BR>

<A HREF="/content/hiv-db/ALIGN_CURRENT/ALIGN-INDEX.html" 
	onMouseOver="document.Alignments.src='/content/hiv-db/NAVIFRAME/YELLOW/_Alignments.gif' "
	onMouseOut="document.Alignments.src='/content/hiv-db/NAVIFRAME/YELLOW/Alignments.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Alignments.gif" BORDER=0 NAME="Alignments"></A><BR>

<A HREF="/content/hiv-db/HTML/Tutorials.html" 
	onMouseOver="document.Tutorials.src='/content/hiv-db/NAVIFRAME/YELLOW/_Tutorials.gif' "
	onMouseOut="document.Tutorials.src='/content/hiv-db/NAVIFRAME/YELLOW/Tutorials.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Tutorials.gif" BORDER=0 NAME="Tutorials"></A><BR>

<A HREF="/content/hiv-db/REVIEWS/reviews.html" 
	onMouseOver="document.Reviews.src='/content/hiv-db/NAVIFRAME/YELLOW/_Reviews.gif' "
	onMouseOut="document.Reviews.src='/content/hiv-db/NAVIFRAME/YELLOW/Reviews.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Reviews.gif" BORDER=0 NAME="Reviews"></A><BR>

<A HREF="/content/hiv-db/HTML/compendium.html" 
	onMouseOver="document.Compendia.src='/content/hiv-db/NAVIFRAME/YELLOW/_Compendia.gif' "
	onMouseOut="document.Compendia.src='/content/hiv-db/NAVIFRAME/YELLOW/Compendia.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Compendia.gif" BORDER=0 NAME="Compendia"></A><BR>

<A HREF="/content/hiv-db/HTML/links.html" 
	onMouseOver="document.Links.src='/content/hiv-db/NAVIFRAME/YELLOW/_Links.gif' "
	onMouseOut="document.Links.src='/content/hiv-db/NAVIFRAME/YELLOW/Links.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Links.gif" BORDER=0 NAME="Links"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<P>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/headerSequenceDB.gif" BORDER=0></A><BR>

<!--
<A HREF="/content/hiv-db/MAP/hivmap.html" 
-->
<A HREF="/content/hiv-db/combined_search/search" 
	onMouseOver="document.Hivmap.src='/content/hiv-db/NAVIFRAME/YELLOW/_Search&Align.gif'"
	onMouseOut="document.Hivmap.src='/content/hiv-db/NAVIFRAME/YELLOW/Search&Align.gif'">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Search&Align.gif" BORDER=0 NAME="Hivmap"></A><BR>

<!--
<A HREF="/cgi-bin/hivDB3/public/wdb/ssampublic" 
-->
<A HREF="/content/hiv-db/combined_search/search" 
	onMouseOver="document.Searchdb.src='/content/hiv-db/NAVIFRAME/YELLOW/_SearchDB.gif' "
	onMouseOut="document.Searchdb.src='/content/hiv-db/NAVIFRAME/YELLOW/SearchDB.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SearchDB.gif" BORDER=0 NAME="Searchdb"></A><BR>

<A HREF="/content/hiv-db/HTML/tools.html" 
	onMouseOver="document.Tools.src='/content/hiv-db/NAVIFRAME/YELLOW/_Tools.gif'"
	onMouseOut="document.Tools.src='/content/hiv-db/NAVIFRAME/YELLOW/Tools.gif'">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Tools.gif" BORDER=0 NAME="Tools"></A><BR>

<A HREF="/content/hiv-db/BASIC_BLAST/basic_blast.html" 
	onMouseOver="document.Hivblast.src='/content/hiv-db/NAVIFRAME/YELLOW/_HIV-BLAST.gif' "
	onMouseOut="document.Hivblast.src='/content/hiv-db/NAVIFRAME/YELLOW/HIV-BLAST.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/HIV-BLAST.gif" BORDER=0 NAME="Hivblast"></A><BR>

<A HREF="http://linker.lanl.gov/RIP/RIPsubmit.html" 
	onMouseOver="document.Rip.src='/content/hiv-db/NAVIFRAME/YELLOW/_Recombination.gif' "
	onMouseOut="document.Rip.src='/content/hiv-db/NAVIFRAME/YELLOW/Recombination.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Recombination.gif" BORDER=0 NAME="Rip"></A><BR>

<A HREF="/content/hiv-db/SNAP/WEBSNAP/SNAP.html" 
	onMouseOver="document.Snap.src='/content/hiv-db/NAVIFRAME/YELLOW/_Syn-Nonsyn.gif' "
	onMouseOut="document.Snap.src='/content/hiv-db/NAVIFRAME/YELLOW/Syn-Nonsyn.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Syn-Nonsyn.gif" BORDER=0 NAME="Snap"></A><BR>

<A HREF="/content/hiv-db/HYPERMUT/hypermut.html" 
	onMouseOver="document.Hypermut.src='/content/hiv-db/NAVIFRAME/YELLOW/_Hypermut.gif' "
	onMouseOut="document.Hypermut.src='/content/hiv-db/NAVIFRAME/YELLOW/Hypermut.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Hypermut.gif" BORDER=0 NAME="Hypermut"></A><BR>

<A HREF="/content/hiv-db/PCOORD/PCOORD.html" 
	onMouseOver="document.Pcoord.src='/content/hiv-db/NAVIFRAME/YELLOW/_PCOORD.gif' "
	onMouseOut="document.Pcoord.src='/content/hiv-db/NAVIFRAME/YELLOW/PCOORD.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/PCOORD.gif" BORDER=0 NAME="Pcoord"></A><BR>
    
<A HREF="/content/hiv-db/SUDI/sudi.html" 
	onMouseOver="document.SUDI.src='/content/hiv-db/NAVIFRAME/YELLOW/_SUDI.gif' "
	onMouseOut="document.SUDI.src='/content/hiv-db/NAVIFRAME/YELLOW/SUDI.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/SUDI.gif" BORDER=0 NAME="SUDI"></A><BR>

<A HREF="/content/hiv-db/CONTAM/TreeMaker/TreeMaker.html" 
	onMouseOver="document.Treemaker.src='/content/hiv-db/NAVIFRAME/YELLOW/_TreeMaker.gif' "
	onMouseOut="document.Treemaker.src='/content/hiv-db/NAVIFRAME/YELLOW/TreeMaker.gif' " >
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/TreeMaker.gif" BORDER=0 NAME="Treemaker"></A><BR>

<A HREF="/content/hiv-db/geography/map_right.html" 
	onMouseOver="document.Geography.src='/content/hiv-db/NAVIFRAME/YELLOW/_Geography.gif' "
	onMouseOut="document.Geography.src='/content/hiv-db/NAVIFRAME/YELLOW/Geography.gif' ">
	
<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/Geography.gif" BORDER=0 NAME="Geography"></A><BR>

<IMG SRC="/content/hiv-db/NAVIFRAME/YELLOW/bottom.gif" BORDER=0></A><BR>

<!--
<br>
<small>
<small>
&nbsp;<a href="/content/hiv-db/combined_search/search">Combined Search</a>
</small>
</small>
</CENTER>
-->
<BR>
<BR>

<center>
<small>
<small>
<A HREF="http://www.lanl.gov/misc/disclaimer.html" >Disclaimer/Privacy</A>
</small>
</small>
<FONT FACE="Arial, Helvetica, sans-serif" SIZE="-2">
</FONT>
</center>

<!--
</BODY>
</HTML>
-->


        </td>
	<td>
	  <table border="0" cellspacing="0" cellpadding="3">
	    <tr><td>
            </td></tr>
	    <tr><td><html>
<title>Brander: HLA Restricted CTL Response</title>
<head>
<body bgcolor = "#FFFFFF">
<DIV align="center"><img src="/IMAGES/ABImmunol.gif"></a><P>
<strong><font size="+3">The HLA Class I Restricted CTL Response in HIV-1 Infection: Systematic Identification of Optimal Epitopes</font></DIV>
<hr size=2>
<br>Christian Brander<sup>1</sup> and Bruce D. Walker<sup>2</sup></strong>
<br><strong><sup>1</sup></strong>AIDS Research Center, Massachusetts General Hospital, 149 13th Street, Room 5234, Charlestown,   MA  02129, USA, and
<br><strong><sup>2</sup></strong>Harvard Medical School Boston,  MA  USA
<p>
<strong>I. Introduction</strong>  
<p>
Viral infection induces CD8+ cytotoxic T lymphocytes (CTL) responses by presenting viral antigen on MHC class I molecules at the surface of
infected cells(1).<a href="#ref01"><sup><strong>1</sup></strong></a> A vigorous CTL response is also associated with Human
Immunodeficiency Virus (HIV) infection (2).<a href="#ref02"><sup><strong>2</sup></strong></a> HIV specific CTL are thought
to play an important role in the control of the virus during clinical
latency and may influence the course of disease development (3-6).<a href="#ref03"><sup><strong>3</sup></strong></a>
Furthermore, experiments in HIV-exposed, uninfected individuals suggest
that CTL could provide protection from infection (7-9).<a href="#ref07"><sup><strong>7</sup></strong></a> The
characterization of the antigenic epitopes involved in CTL induction is
important not only for a better understanding of disease pathogenesis, but
also for possible vaccine development. Since the first description of HIV
specific CTL, the efforts of many laboratories have led to the
identification of a large number of epitopes involved in the HIV-1
specific CTL response in infected persons(10, 11).<a href="#ref10"><sup><strong>10;</sup></strong></a><a href="#ref11"><sup><strong>11</sup></strong></a> A summary of those sequences is accessible in this database. It contains more than 200 peptides, which
contain putative HLA class I restricted epitopes. In many cases, these
peptides require further definition as to the minimal epitope or the
restricting HLA molecule. Here, we have compiled a list of peptides that
have been defined in terms of the minimal length that mediates the most
effective target cell sensitization in the context of the restricting class
I molecule. More than 60 peptides fulfilling these criteria were included
in the last database update (11).<a href="#ref11"><sup><strong>11</sup></strong></a> Within the last 12 months, more than 30
new optimal epitopes have been identified, many of which are not yet
published or are in submitted reports.
<p>
<strong>II.  Presentation and recognition of viral antigen on MHC class I</strong>  
<p>
Recent advances in the understanding of MHC class I antigen processing have
provided insights into peptide selection for CTL responses. Viral antigen
is presented to specific T cells as short peptides in association with MHC
molecules (1, 12).<a href="#ref01"><sup><strong>1;</sup></strong></a><a href="#ref12"><sup><strong>12</sup></strong></a> These antigenic
epitopes are derived from viral cytosolic proteins which undergo proteasome
mediated processing (3, 13).<a href="#ref03"><sup><strong>3;</sup></strong></a><a href="#ref13"><sup><strong>13</sup></strong></a> A number of parameters likely influence
peptide processing, including amino acids both within and outside the CTL
epitope in the cytosol(14).<a href="#ref14"><sup><strong>14</sup></strong></a> Following processing, the peptides are translocated into the lumen of the ER by  the TAP1/TAP2 heterodimer and bound to nascent MHC
class I molecules. Both interactions (TAP and MHC) seem to have restrictive
specificities and to allow only some peptides to be presented (3, 13,
15).<a href="#ref03"><sup><strong>3;</sup></strong></a><a href="#ref13"><sup><strong>13;</sup></strong></a><a href="#ref15"><sup><strong>15</sup></strong></a> Whereas peptide binding to MHC molecules has been extensively
studied, both the impact of different TAP-alleles on the generation of peptides
and the link between TAP alleles and  HLA alleles are unclear (15-17).<a href="#ref15"><sup><strong>15</sup></strong></a>
As revealed by peptide titration studies and peptide elution from the
isolated MHC class I molecule,  HLA class I restricted epitopes normally
are about 8-12 amino acids in length and have certain anchor residues to
bind into specific pockets of the MHC class I molecule. These pockets,
designated A, B, C, D, E and F, are located in the antigen binding site on
the class I molecule formed by two alpha helices, with the floor of the
groove formed by a beta-sheet structure (18).<a href="#ref18"><sup><strong>18</sup></strong></a> As the pockets are located
at the edge of the peptide binding groove, the anchor positions in the
peptides are often in positions 1, 2 and 9 of the processed peptide (19).<a href="#ref19"><sup><strong>19</sup></strong></a>
However, other residues can influence the peptide binding as well (20).<a href="#ref20"><sup><strong>20</sup></strong></a>
Eluting peptides from various MHC class I molecules has led to the definition
of MHC-allele-specific binding motifs (19-21).<a href="#ref19"><sup><strong>19;</sup></strong></a> These motifs can be used
to screen protein sequences in order to find potentially antigenic epitopes
presented by a certain HLA allele (22).<a href="#ref22"><sup><strong>22</sup></strong></a> However, this approach only
reflects peptide binding but not necessarily their involvement in the
natural CTL response  <i> in vivo,</i> as such evaluations do not analyze the
effects of protein processing and transportation.
Very recently, the x-ray crystal structure and orientation of a T cell
receptor (TCR) bound to a MHC/peptide complex was described (23).<a href="#ref23"><sup><strong>23</sup></strong></a> The V
region of the alpha and the beta chains, resembling antibody structures, contacts the presented peptide in its core region through the third
complementarity-determining regions (CDR 3), forming a deep hydrophobic
cavity. The CDR1 and CDR2 regions of the alpha-chain appear to contact the
MHC/peptide complex around the N-terminal end of the embedded peptide,
whereas the beta chain CDR1 and CDR2 contact  the C-terminus of the peptide.
These findings may help to explain the biased use of certain V-beta chain
segments observed in various immune responses, i.e. influenza infection and
different autoimmune diseases (24, 25).<a href="#ref25"><sup><strong>25;</sup></strong></a><a href="#ref24"><sup><strong>24</sup></strong></a>
<p>
<strong>III.  Identification of HIV-1 derived CTL epitopes</strong>
<p>
Various methods have been used to identify HIV-1-derived, HLA class I
restricted epitopes. The majority of epitopes have been defined using CTL
lines or clones recognizing recombinant viral antigen, such as target cells
infected with vaccinia virus  constructs expressing selected HIV-1
proteins. The minimal epitope for these responses is determined by using
synthetic peptides, followed by titration assays with truncated peptides to
identify the optimal epitope (26).<a href="#ref26"><sup><strong>26</sup></strong></a> Alternatively, binding-motif based
searches for potential epitopes has led to the identification of some
optimal epitopes (22).<a href="#ref22"><sup><strong>22</sup></strong></a> However, to prove that the binding peptide is
involved in the natural immune response to HIV, recognition of the
naturally processed peptide by CTL in infected persons is required.
Finally, elution of peptide from HLA class I molecules allows for the
direct isolation of processed, class I binding epitopes (27).<a href="#ref27"><sup><strong>27</sup></strong></a> However,
these epitopes are not necessarily immunogenic  <i> in vivo</i> and may thus not
induce a CTL response in infected humans.
<p>
In published studies, different methods have been used to identify optimal
epitopes. In some cases the HLA restriction has not been shown or the
optimal epitope has not been defined by titration assays using truncated
peptides. The Los Alamos HIV Molecular Immunology Database contains all
reported sequences with CTL activity, regardless of their definition as optimal
epitopes. However, for many different questions and approaches such as the
design of a epitope based vaccine, the knowledge of the optimal epitope is a
prerequisite. In the list presented here (Table 1), we include only those
peptides which fit rigid criteria: 1) the CTL recognize the naturally
processed epitope, 2) titration assays with truncated peptides have
identified the optimal epitope and 3) the restricting HLA molecule has been
defined. A number of likely optimal epitopes were not included as these
criteria were not met. For example, we did not include putative HLA-Cw8
restricted epitopes, since Cw8 is in a strong linkage disequilibrium with
HLA-B14 and it is thus difficult to identify the restricting HLA allele by
using (mis)matched cell lines (28, 29).<a href="#ref28"><sup><strong>28;</sup></strong></a><a href="#ref29"><sup><strong>29</sup></strong></a> However, these sequences can be
found in other parts of the database.
<br>
<img src="Brander961.gif">
<br>
<img src="Brander962.gif">
<br>
<img src="Brander963.gif">
<br>
<img src="Brander964.gif">
<br>
<img src="Brander965.gif">
<p>
<strong>IV.  Analysis of HIV-1 derived CTL epitopes</strong>  
<P>
The list of HIV derived CTL epitopes will continue to grow, as new epitopes
are found and longer sequences are mapped to the optimal epitope. The list
given in Table 1 should provide investigators with a reliable compilation
of optimal CTL epitopes in HIV. With the growing number of defined
optimal epitopes, some interesting characteristics are beginning to emerge.
More epitopes which overlap with previously described ones have been
identified, as have epitopes which can be restricted by multiple HLA
alleles. These latter epitopes could be interesting candidates for peptide based
vaccine development. This is the case for RT protein derived epitope
AIFQSSMTK (a.a.325- a.a.333) which binds to HLA-A3 and HLA-A11, both
members of the same binding motif superfamily (30).<a href="#ref30"><sup><strong>30</sup></strong></a> The gag-p17 derived
peptide RLRPGGKKKY (a.a. 20-29) was found to be presented by at least three
different HLA alleles (HLA-A3, -B42, -Bw62). Additional examples of
epitopes binding to multiple HLA molecules are included in this list and
can be conveniently found by searching the Los Alamos Database.
Furthermore, it becomes clear that some areas contain multiple overlapping
peptides. By minute alteration (i.e. truncation by or substitution of one
amino acid), those epitopes may be able to bind to additional HLA molecules
without losing the binding affinity to the original HLA molecule(s) nor
escaping recognition by CTL specific for the original peptide.
Different studies have shown that there can be wide cross recognition of
variants of certain epitopes (8, 31, 32).<a href="#ref08"><sup><strong>8;</sup></strong></a><a href="#ref31"><sup><strong>31;</sup></strong></a><a href="#ref32"><sup><strong>32</sup></strong></a> This would suggest that a
less conserved, but highly immunodominant epitope may serve as a superior
immunogen for vaccine development than one which is highly conserved, but
only rarely recognized. However, one must consider the potential adverse
effects of sequence variation within, or flanking, these epitopes which may
alter peptide processing and presentation. In general, it seems that the
induction of a strong CTL response requires epitopes that bind tightly to
the class I molecule. It has been suggested that the immunogenicity of
potential CTL epitopes can be predicted more accurately by the dissociation
rate than by the binding affinity (33).<a href="#ref33"><sup><strong>33</sup></strong></a>
Although Table 1 lists numerous epitopes, little is known about their
potential immunodominance, which may be especially important with regard to
the development of peptide based vaccines (32, 34).<a href="#ref32"><sup><strong>32;</sup></strong></a><a href="#ref34"><sup><strong>34</sup></strong></a> The mechanisms
leading to such immunodominance are not clear, although several reasons
have been discussed. These include the preferential processing of certain
epitopes by the proteasome due to favored flanking regions, the binding
affinity to the class I molecule, the peptide selectivity of the TAP dimer,
and a lack in the T cell repertoire. Thus, epitopes selected as peptide
vaccine candidates may need to be tested not only for variability and
binding affinities but rather for parameters like dissociation rate and
immunodominance.
<p>
<strong>Acknowledgments</strong>
<p>
We would like to thank all the investigators who contributed unpublished
data for inclusion in this list and in the Los Alamos HIV Molecular
Immunology Database. This work was supported by the Schweizerische Stiftung
fuer Medizinisch Biologische Stipendien, the Swiss National Foundation,
NIH grants A128568 and A130914, and by a grant from the Pediatric AIDS
Foundation (ARIEL Project for the prevention of HIV-transmission from
mother to infant).
<p>
<strong>References</strong>
<p>
<a name="ref01"><strong>1. </strong>
Oldstone MBA. (1989). Viral persistence. <i>Cell</i> <strong>56:</strong> 517-520.
<p>
<a name="ref02"><strong>2. </strong>
McMichael AJ  and  Walker BD. (1994). Cytotoxic T lymphocyte epitopes:  Implications for HIV vaccines. <i>AIDS</i> <strong>8 (suppl 1):</strong> S155-S173.
<p>
<a name="ref03"><strong>3. </strong>
York IA and Rock KL. (1996). Antigen processing and presentation by the class I major histocompatibility complex. <i>Ann. Rev. Immunol.</i> <strong>14:</strong> 369-396.
<p>
<a name="ref04"><strong>4. </strong>
Koup RA,  Safrit JT,  Cao Y,  Andrews CA,  McLeod G,  Borkowsky W   Farthing C.  and  Ho DD. (1994). Temporal association of cellular immune responses  with the initial control of viremia in primary human immunodeficiency virus  type 1 syndrome. <i>J. Virol.</i> <strong>68:</strong> 4650-4655.
<p>
<a name="ref05"><strong>5. </strong>
Klein MR  and  Van Baalen CA. (1995). Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. <i>J. Exp. Med.</i> <strong>181:</strong> 1356-1372.
<p>
<a name="ref06"><strong>6. </strong>
Harrer T,  Harrer E,  Kalams SA,  Elbeik T,  Staprans SI,  Feinberg MB,  Cao Y,   Ho DD,  Yilma T,  Caliendo AM,  Johnson RP,  Buchbinder SP  and  Walker BD. (1995). Strong  cytotoxic T cell and weak neutralizing antibody responses in a subset of persons  with stable nonprogressing HIV type 1 infection. <i>AIDS Res. Human Retrov.</i> <strong>12:</strong> 585-592.
<p>
<a name="ref07"><strong>7. </strong>
Rowland-Jones SL,  Nixon DF,  Aldhous MC,  Gotch F,  Ariyoshi K,  Hallam N,  Kroll JS,   Froebel K  and  McMichael A. (1993). HIV-specific cytotoxic T-cell activity in an  HIV-exposed but uninfected infant. <i>Lancet</i> <strong>341:</strong> 860-861.
<p>
<a name="ref08"><strong>8. </strong
>Rowland-Jones S,  Sutton J,  Ariyoshi K,  Dong T,  Gotch F,  McAdam S, Whitby D,  Sabally S,  Gallimore A,  Corrah T,  Takiguchi M,  Schultz T, McMichael A  and  Whittle H. (1995). HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. <i>Nature Medicine</i> <strong>1:</strong> 59-64.
<p>
<a name="ref09"><strong>9. </strong>
Pinto LA,  Sullivan J,  Berzofsky JA,  Clerici M,  Kessler HA,   Landay AL  and  Shearer GM. (1995). Env-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV contaminated body fluids. <i>J. Clin. Invest.</i> <strong>96:</strong> 867-876.
<p>
<a name="ref10"><strong>10. </strong>
Walker BD,  Chakrabarti S,  Moss B,  Paradis TJ,  Flynn T,  Durno AG,  Blumberg RS,   Kaplan JC,  Hirsch MS  and  Schooley RT. (1987). HIV-specific cytotoxic T lymphocytes  in seropositive individuals. <i> Nature</i> <strong>328:</strong> 345-8.
<p>
<a name="ref11"><strong>11. </strong>
Brander C  and  Walker BD. (1995). The HLA class I restricted CTL response in HIV infection: identification of optimal epitopes. From: <i>HIV Molecular Immunology Database 1995.</i> Editors: Korber BTM,  Brander C,  Walker BD,  Koup R,  Moore JP, Haynes BF  and  Myers G. Publisher: Los Alamos National Laboratory: Theoretical Biology and  Biophysics, Los Alamos, NM, USA. <strong>IV:</strong> 1-9.
<p>
<a name="ref12"><strong>12. </strong>
Goldberg AL  and  Rock KL. (1992). Proteolysis, proteasomes and antigen presentation. <i>Nature</i> <strong>357:</strong> 375-379.
<p>
<a name="ref13"><strong>13. </strong>
Rammensee HG, Falk K  and  Roetzschke O. (1993). MHC molecules as peptide receptors. <i>Curr. Opin. Immunol.</i> <strong>5:</strong> 35-44.
<p>
<a name="ref14"><strong>14. </strong>
Bergmann CC,  Yao Q,  Ho C  and  Buckwold SL. (1996). Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. <i>J. Immunol.</i> <strong>157:</strong> 3242-3249.
<p>
<a name="ref15"><strong>15. </strong>
Heemels M  and  Ploegh HL. (1994). Substrate specificity of allelic variants of the TAP peptide transporter. <i>Immunity</i> <strong>1:</strong> 775-784.
<p>
<a name="ref16"><strong>16. </strong>
Shepherd JC,  Schumacher TNM,  Ashton-Rickardt PG,  Imaeda S, Ploegh HL,  Janeway CA  and  Tonegawa S. (1993). TAP 1-dependent peptide
translocation  <i> in vitro</i> is ATP dependent and peptide selective. <i>Cell</i>
<strong>74:</strong> 577-584.
<p>
<a name="ref17"><strong>17. </strong>
Obst R,  Armandola EA,  Nijenhuis M,  Momburg F  and  Haemmerling GJ. (1995). 
TAP polymorphism does not influence transport of peptide variants in mice and humans. <i>Eur. J. Immunol.</i> <strong>25:</strong> 2170.
<p>
<a name="ref18"><strong>18. </strong>
Bjorkman P,  Saper M,  Samraoui B,  Bennett W,  Strominger J  and  Wiley D. (1987). Structure of human class I histocompatibility antigen, HLA-A2. <i> Nature</i> <strong>329:</strong> 506-511.
<p>
<a name="ref19"><strong>19. </strong>
Falk K,  Rotzschke O,  Deres K,  Metzger J,  Jung G  and  Rammensee HG. (1991). 
Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. <i>J. Exp. Med.</i> <strong>174:</strong> 425-434.
<p>
<a name="ref20"><strong>20. </strong>
Ruppert J,  Sidney J,  Celis E,  Kubo RT,  Grey HM  and  Sette A. (1993). Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. <i>Cell</i> <strong>74:</strong> 929-937.
<p>
<a name="ref21"><strong>21. </strong>
Falk K,  Rotzschke O,  Stevanovic S,  Jung G  and  Rammensee HG. (1991). Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. <i>Nature</i> <strong>351:</strong> 290-296.
<p>
<a name="ref22"><strong>22. </strong>
Hobohm U  and  Meyerhans A. (1993). A pattern search method for putative anchor 
residues in T cell epitopes. <i>Eur. J. Immunol.</i> <strong>23:</strong> 1271-1275.
<p>
<a name="ref23"><strong>23. </strong>
Garcia KC,  Degano M,  Stanfield RL,  Brunmark A,  Jackson MR,  Peterson PA,  
Teyton L  and  Wilson IA. (1996). An a/b T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. <i>Science</i> <strong>274:</strong> 209-219.
<p>
<a name="ref24"><strong>24. </strong>
Lehner PJ,  Wang EC,  Moss PAH,  Williams S,  Platt K,  Friedman SM,  Bell JI  and  Borysiewicz LK. (1995). Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of Influenza A is dominated by T cells bearing the Vb17 gene segment. <i>J. Exp. Med.</i> <strong>181:</strong> 79-91.
<p>
<a name="ref25"><strong>25. </strong>
Moss PA,  Rosenberg WM  and  Bell JI. (1992). The human T cell receptor in health and disease. <i>Ann. Rev. Immunol.</i> <strong>10:</strong> 71-96.
<p>
<a name="ref26"><strong>26. </strong>
Gnann JWJ,  Nelson JA  and  Oldstone MB. (1987). Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. <i>J. Virol.</i> <strong>61:</strong> 2639-2641.
<p>
<a name="ref27"><strong>27. </strong>
Tsomides TJ,  Aldovini A,  Johnson RP,  Walker BD,  Young RA  and  Eisen HN. (1994). Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1 (HIV-1). <i>J. Exp. Med.</i> <strong>180:</strong> 1283-1293.
<p>
<a name="ref28"><strong>28. </strong>
Trowsdale J,  Ragoussis J  and  Campbell RD. (1991). Map of the human MHC. 
<i>Immunology Today</i> <strong>12:</strong> 443-446.
<p>
<a name="ref29"><strong>29. </strong>
Sipsas NV,  Kalams SA,  Trocha A,  He S,  Blattner WA,  Walker BD  and  Johnson RP. (1996). Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with the human immunodeficiency virus-1. <i>J. Clin. Invest.</i> <strong>In press.</strong>
<p>
<a name="ref30"><strong>30. </strong>
Threlkeld SC,  Wentworth P,  Kalams S,  Johnson P,  Wilkens BM,  Ruhle DJ,  Sidney J, Walker BD  and  Sette A. (1996). Degenerate and promiscuous recognition by cytotoxic T lymphocyte (CTL) of peptides presented by the MHC class I A3-like superfamily: Implications for vaccine development. <strong>Submitted.</strong>
<p>
<a name="ref31"><strong>31. </strong>
Safrit J,  Andrews CA,  Tuofu Z,  Ho DD  and  Koup RA. (1994). Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: Recognition of autologous virus sequences within a conserved immunodominant epitope. <i>J. Exp. Med.</i> <strong>179:</strong> 463-472.
<p>
<a name="ref32"><strong>32. </strong>Brander C,  Hartman KE,  Trocha AK,  Jones ND,  He S,  Wentworth P,  Hermanson G, Buchbinder SP,  Johnson RP,  Walker BD  and  Kalams SA. (1996). Identification of the immunodominant HLA-A*02.01 restricted CTL responses in HIV infection: strong CTLresponses contrast with only rare occurrence of potential viral escape variants. <strong>Submitted.</strong>
<p>
<a name="ref33"><strong>33. </strong>Van der Burg S,  Visseren MJ,  Brandt RM,  Kast WM  and  Melief CJ. (1996). Immunogenicity of peptides bound to MHC class I molecules depends on the MHC peptide complex stability. <i>J. Immunol.</i> <strong>156:</strong> 3308-3314.
<p>
<a name="ref34"><strong>34. </strong>
Shiga H,  Shioda T,  Tomiyama H,  Takamiya Y,  Oka S,  Kimura S,  Yamaguchi Y,  Gojoubori T, Rammensee HG,  Miwa K  and  Takiguchi M. (1996). Identification of multiple HIV-1 cytotoxic T-cell
epitopes presented by human leukocyte antigen B35 molecule. <i>AIDS</i> </strong>10:</strong> 1075-1083.
<p>
<a name="ref35"><strong>35. </strong>Johnson RP,  Trocha A,  Yang L,  Mazzara GP,  Panicali DL,  Buchanan TM  and Walker BD. (1991). HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned  effector cells. <i>J. Immunol.</i> <strong>147:</strong> 1512-1521.
<p>
<a name="ref36"><strong>36. </strong>
Parker KC,  Bednarek MA,  Hull LK,  Utz U,  Cunningham B,  Zweerink HJ,
Biddison WE  and  Coligan JE. (1992).  Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. <i>J. Immunol</i>. <strong>149:</strong> 3580- 3587.
<p>
<a name="ref37"><strong>37. </strong>
Parker KC,  Bednarek MA  and  Coligan JE. (1994). Scheme for ranking potential
HLA-A2 binding peptides based on  independent binding of individual peptide
side-chains. <i>J. Immunol.</i> <strong>152:</strong>163-175.
<p>
<a name="ref38"><strong>38. </strong>
Walker BD,  Flexner C, Birch-Limberger K,  Fisher L, Paradis TJ, Aldovini A, 
Young R,  Moss B  and  Schooley  RT. (1989). Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human  immunodeficiency virus type 1. <i>Proc. Natl. Acad. Sci. USA.</i> <strong>86: </strong>9514-9518.
<p>
<a name="ref39"><strong>39. </strong>
Tsomides TJ,  Walker BD  and  Eisen HN. (1991). An optimal viral peptide
recognized by CD8+ T cells binds very  tightly to the restricting class I major
histocompatibility complex protein on  intact cells but not to the purified
class I  protein. <i>Proc. Natl. Acad. Sci. USA.</i> <strong>88:</strong> 11276-11280.
<p>
<a name="ref40"><strong>40. </strong>
Dupuis M,  Kundu SK  and  Merigan TC. (1995). Characterization of HLA-A*0201-restricted cytotoxic T cell epitopes  in conserved regions of the HIV
type 1 gp160 protein. <i>J. Immunol.</i> <strong>155:</strong> 2232-2239. 
<p>
<a name="ref41"><strong>41. </strong>
Haas G,  Plikat U,  Debre P,  Lucchiari M,  Katlama C,  Dudoit Y, Bonduelle O,  Bauer M,  Ihlenfeldt H,  Jung G,  Maier B,  Meyerhans A  and  Autran B. (1996). Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes <i>in vivo</i>. <i>J. Immunol.</i> <strong>157:</strong> 4212-4221.
<p>
<a name="ref42"><strong>42. </strong>
Hadida F,  Haas G,  Zimmermann G, Hosmalin A, Spohn R, Samri A, Jung G, Debre P  and Autran B. (1995). CTLs  from lymphoid organs recognize an optimal HLA-A2 restricted and HLA-B52-restricted nonapeptide and several epitopes  in the C-terminal region of HIV-1 Nef. <i>J. Immunol<i> .</strong>154:</strong>4174-4186.
<p>
<a name="ref43"><strong>43. </strong>
DiBrino M,  Parker KC,  Shiloach J,  Knierman M,  Lukszo J,  Turner RV, Biddison WE  and  Coligan JE. (1993).  Endogenous peptides bound to HLA-A3 possess a
specific combination of anchor residues that permit identification of  potential
antigenic peptides. <i>Proc. Natl. Acad. Sci. USA.</i> <strong>90:</strong> 1508-1512.
<p>
<a name="ref44"><strong>44. </strong>
Harrer T,  Harrer E,  Kalams SA,  Barbosa P,  Trocha A,  Johnson RP, Elbeik T,  Feinberg MB,  Buchbinder SP  and  Walker BD. (1996). Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to <i>in vivo</i> viral quasispecies in a person with prolonged infection and low viral load. <i>J. Immunol.</i> <strong> 156:</strong> 2616-2623.
<p>
<a name="ref45"><strong>45. </strong>
Johnson RP, Hammond SA, Trocha A, Siliciano RF  and  Walker BD. (1994). Inductionof a major histocompatibility  complex class I-restricted cytotoxic T lymphocyte response to a highly conserved region of human immunodeficiency  virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. <i>J. Virol.</i> <strong>68:</strong> 3145- 3153.
<p>
<a name="ref46"><strong>46. </strong>
Takahashi K,  Dai LC,  Fuerst TR,  Biddison WE,  Earl PL,  Moss B  and  Ennis
FA. (1991).  Specific lysis of  human immunodeficiency virus type 1-infected
cells by  a HLA-A3.1-restricted CD8+ cytotoxic T-lymphocyte clone  that
recognizes a conserved peptide sequence within the gp41 subunit of the envelope 
protein. <i>Proc. Natl. Acad. Sci. USA.</i> <strong>88:</strong>10277-10281.
<p>
<a name="ref47"><strong>47. </strong>
Koenig S,  Fuerst TR,  Wood LV,  Woods RM,  Suzich JA,  Jones GM,  de la Cruz
VF,  Davey RT Jr,   Venkatesan S,  Moss B.  et al. (1990).  Mapping the fine
specificity of a cytolytic T cell response to HIV-1 nef protein. <i>J. Immunol. 
</i> <strong>145:</strong> 127-135.
<p>
<a name="ref48"><strong>48. </strong>
Culmann B,  Gomard E,  Kieny MP,  Guy B,  Dreyfus F,  Saimot AG,   Sereni D, 
Sicard D  and  Levy JP. (1991).  Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 Nef protein. <i>J. Immunol.</i> <strong>146:</strong> 1560-1562.
<p>
<a name="ref49"><strong>49. </strong>
Zhang QJ,  Gavioli R,  Klein G  and  Masucci MG. (1993).  An HLA-A11-specific
motif in nonamer peptides derived  from viral and cellular proteins. <i>Proc. Natl. Acad. Sci. USA.</i> <strong>90:</strong> 2217-2221.
<p>
<a name="ref50"><strong>50. </strong>
Johnson RP  and  Walker BD. (1994). CTL in HIV-1 infection: Responses to structural proteins. <i>J. Curr. Topics.  Microbiol. Immunol.</i> <strong> 189:</strong> 35-63.
<p>
<a name="ref51"><strong>51. </strong>
Lieberman J, Fabry JA, Kuo MC, Earl F, Moss B  and  Skolnik PR. (1992). Cytotoxic T lymphocytes from HIV-1  seropositive individuals recognize immunodominant epitopes in gp160 and reverse transcriptase. <i>J. Immunol.</i>  <strong>148:</strong> 2738-2747
<p>
<a name="ref52"><strong>52. </strong>
Shankar P, Fabry JA, Fong D  and  Lieberman J. (1995). Three regions of gp160
contain overlapping CTL epitopes  restricted by multiple HLA class I alleles.
(abstract) <i>J. Cellular. Biochem.</i> S21B: D4-345.
<p>
<a name="ref53"><strong>53. </strong>
Dai LC,  West K,  Littaua R,  Takahashi K  and  Ennis FA. (1992). Mutation of
human immunodeficiency virus type  1 at amino acid 585 on  gp41 results in loss
of killing by CD8+ A24-restricted cytotoxic T  lymphocytes. <i>J. Virol.</i>  
<strong>66:</strong>3151-3154.
<p>
<a name="ref54"><strong>54. </strong>
Klenerman P,  Luzzi G,  McIntyre K,  Phillips R  and  McMichael A. (1996).
Identification of a novel HLA-A25 restricted epitope in a conserved region
of p24 gag (positions 71-80). <i>AIDS.</i> <strong>10:</strong>348-350.
<p>
<a name="ref55"><strong>55. </strong>
Van Baalen CA,  Klein MR,  Huisman RC,  Dings ME,  Kerkhof Garde SR,  
Geretti AM,  Gruters R,  Van Els CA,  Miedema F  and  Osterhaus AD. (1996). 
Fine-specificity of cytotoxic T lymphocytes which recognize conserved 
epitopes of the Gag protein of human immunodeficiency virus type 1. 
<i>J. Gen. Virol.</i> <strong>77:</strong> 1659-1665.
<p>
<a name="ref56"><strong>56. </strong>
Safrit JT,  Lee AY,  Andrews CA  and  Koup RA. (1994). A region of the third
variable loop of HIV-1 gp120 is  recognized by  HLA-B7-restricted CTLs from two
acute seroconversion patients. <i>J. Immunol.</i> <strong>153:</strong> 3822-3830.
<p>
<a name="ref57"><strong>57. </strong>
Safrit JT,  Andrews CA,  Zhu T,  Ho DD  and  Koup RA. (1994). Characterization of human immunodeficiency virus  type 1-specific  cytotoxic T lymphocyte clones
isolated during acute seroconversion: recognition of autologous virus  sequences
within a conserved  immunodominant epitope. <i>J. Exp. Med.</i> <strong> 179:</strong> 463-472.
<p>
<a name="ref58"><strong>58. </strong>Engelhard VH, Huczko EL  and  Bodener W. (1993). Peptides bound to HLA-B7 determined by mass spectrometry  (abstract) <i>J. Cell. Biochem. Suppl.</i> 17C:56.
<p>
<a name="ref59"><strong>59. </strong>
Culmann-Penciolelli B, Lamhamedi-Cherradi S, Couillin I, Guegan N, Levy JP, 
Guillet JG  and  Gomard E. (1994).  Identification of multirestricted  immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 nef  protein. <i>J. Virol.</i> <strong> 68:</strong> 7336-7343.
<p>
<a name="ref60"><strong>60 </strong>
Hill AV,  Elvin J,  Willis AC,  Aidoo M,  Allsopp CE  and  Gotch FM. (1992). Molecular analysis of the association  of HLA-B53 and resistance to severe malaria. <i> Nature.</i>  <strong>360:</strong> 434-439. 
<p>
<a name="ref61"><strong>61. </strong>
Sutton J,  Rowland-Jones S,  Rosenberg W,  Nixon D,  Gotch F,  Gao XM, Murray
N,  Spoonas A,  Driscoll P,   Smith M. Willis A  and  McMichael AJ. (1993). A
sequence pattern for peptides presented to cytotoxic T lymphocytes by  HLA B8
revealed by analysis of epitopes and eluted peptides. Eur. <i> J. Immunol.</i>  
<strong>23:</strong> 447-453. 
<p>
<a name="ref62"><strong>62. </strong>
Rowland-Jones SL,  Powis SH,  Sutton J,  Mockridge I,  Gotch FM,   Murray N, 
Hill AB,  Rosenberg WM,   Trowsdale J  and  McMichael AJ. (1993).  An antigen
processing polymorphism revealed by HLA-B8-restricted  cytotoxic T  lymphocytes
which does not correlate with TAP gene  polymorphism. Eur.  <i> J. Immunol.</i> 
<strong>23:</strong> 1999-2004. 
<p>
<a name="ref63"><strong>63. </strong>
Johnson RP,  Trocha A,  Buchanan TM  and  Walker BD. (1992). Identification of
overlapping HLA class I-restricted  cytotoxic T cell epitopes in a conserved
region of the human immunodeficiency virus type 1 envelope glycoprotein: 
definition of minimum epitopes and analysis of the effects of sequence
variation. <i>J. Exp. Med.</i> <strong>175:</strong> 961-971. 
<p>
<a name="ref64"><strong>64. </strong>
DiBrino M,  Parker KC,  Margulies DH,  Shiloach J,  Turner RV,  Garfield M,
Biddison WE  and  Coligan JE.   (1994). The HLA-B14 peptide binding site can
accommodate peptides with different combinations of anchor residues. <i>J.  Biol. Chem.</i> <strong>269:</strong> 32426-32434. 
<p>
<a name="ref65"><strong>65. </strong>
Nixon DF  and  McMichael AJ. (1988). Cytotoxic T cell recognition of HIV proteins and peptides. <i>AIDS.</i> <strong>5:</strong> 1049-1059. 
<p>
<a name="ref66"><strong>66. </strong>
Jardetzky TS,  Lane WS, Robinson RA,  Madden DR  and  Wiley DC. (1991).
Identification of self peptides bound to  purified HLA-B27. <i>Nature.</i>   <strong>353:</strong> 326-329. 
<p>
<a name="ref67"><strong>67. </strong>
Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J  and  McMichael A. (1988).
HIV-1 gag specific cytotoxic T  lymphocytes defined with recombinant vaccinia
virus and synthetic peptides. <i>Nature.</i> <strong>336:</strong> 484-487. 
<p>
<a name="ref68"><strong>68. </strong>
Buseyne F,  McChesney M,  Porrot F,  Kovarik S,  Guy B  and  Riviere Y. (1993).
Gag-specific cytotoxic T  lymphocytes from human immunodeficiency virus type
1-infected individuals: Gag epitopes are clustered in three  regions of the p24
gag protein. <i>J. Virol.</i> <strong>67:</strong> 694-702. 
<p>
<a name="ref69"><strong>69. </strong>Rowland-Jones S,  Sutton J,  Ariyoshi K, et al. (1995). HIV-specific cytotoxic T-cells in HIV-exposed but  uninfected Gambian women. <i>Nature Med.</i> <strong>1:</strong> 59--64. 
<p>
<a name="ref70"><strong>70. </strong>
Gotch F,  McAdam SN, Allsopp CE, Gallimore A, Elvin J, Kieny MP, Hill AV  and  
McMichael AJ. (1993).  Cytotoxic T cells in HIV-2 seropositive Gambians.
Identification of a virus-specific MHC-restricted peptide epitope. <i>J. Immunol.</i> <strong>151:</strong> 3361-3369. 
<p>
<a name="ref71"><strong>71. </strong>
Falk K,  R&#246tzschke O  and  Grahovac B.  (1994). Allele specific peptide motifs of HLA-C molecules. <i>Proc. Natl. Acad.  Sci. USA.</i> <strong> 90:</strong> 12005-12009. 
<p>
<a name="ref72"><strong>72. </strong>
Johnson RP,  Trocha A,  Buchanan TM  and  Walker BD. (1993). Recognition of a
highly conserved region of human  immunodeficiency virus type 1 gp120 by an
HLA-Cw4 restricted cytotoxic T lymphocyte clone. <i>J. Virol.</i> <strong> 67:</strong> 438-445. 
<p>
<a name="ref73"><strong>73. </strong>
Wilson CC, Kalams SA, Wilkes BA, Ruhl DH, Gao F, Hahn BH, Hanson IC,Luzuriaga K, Wolinsky S, Koup R, Buchbinder SP, Johnson RP, and Walker BD. (1996).Overlapping Epitopes in Human Immunodeficiency Virus Type 1 gp120 presented by HLA A, B and C Molecules: Effects of viral variation on Cytotoxic T-Lymphocyte Recognition. <i>J. Virol.</i> <strong>71:</strong> 1256-1264. 
<p>
<a name="ref74"><strong>74. </strong>
Harrer E, Harrer T, Barbosa P, Feinberg M, Johnson RP, Buchbinder S and Walker BD (1996). Recognition of Highly Conserved YMDD Region in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase by HLA-A2-Restricted Cytotoxic T Lymphocyte from an Asymptomatic Long-Term NonProgressor. <i>J. of Infectious diseases.(Feb 1996)</i> <strong>173(2):</strong> 476-479
</td></tr>
	    <tr><td><table bgcolor="white" width="100%" align="center" cellpadding="0" cellspacing="0" border="0">
  <tr><td>&nbsp;</td></tr>
  <tr><td colspan=2 align=center>Questions or comments? Contact us at <a href="mailto:seq-info@t10.lanl.gov"><font color="#8f8fbd" face="helvetica">seq-info@t10.lanl.gov</font></a></td></tr>
  <tr><td>&nbsp;</td></tr>
</table>



</td></tr>
	  </table>  
        </td>
      </tr>	
    </table>
  </body>
</html>      

<!-- no autohandlers upstream -->


